Biodistribution and dosimetry of 177Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma

Current Radiopharmaceuticals

Volumn 6, Issue 1, 2013, Pages 20-27

  Repetto Llamazares, Ada H V ^a,b   Larsen, Roy H ^c   Mollatt, Camilla ^b   Lassmann, Michael ^d   Dahle, Jostein ^a  

^a Nordic Nanovector AS   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Sciencons Ltd   (Norway)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CD37; Lutetium 177; Non Hodgkin lymphoma; Radioimmunotherapy

Indexed keywords

IBRITUMOMAB TIUXETAN; RADIOPHARMACEUTICAL AGENT; TETRAXETAN RITUXIMAB LU 177; TETRAXETAN TETULOMAB LU 177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUTETIUM; LYMPHOMA, NON-HODGKIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIATION DOSAGE; RADIOISOTOPES; TISSUE DISTRIBUTION;

EID: 84881592277     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011306010004     Document Type: Article

References (40)

1. Foran, J.M.; Norton, A.J.; Micallef, I.N.; Taussig, D.C.; Amess, J.A.; Rohatiner, A.Z.; Lister, T.A. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br. J. Haematol., 2001, 114(4), 881-883.
2. Sugimoto, T.; Tomita, A.; Hiraga, J.; Shimada, K.; Kiyoi, H.; Kinoshita, T.; Naoe, T. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem. Biophys. Res. Commun., 2009, 390(1), 48-53.
3. Wada, N.; Kohara, M.; Ogawa, H.; Sugiyama, H.; Fukuhara, S.; Tatsumi, Y.; Kanamaru, A.; Hino, M.; Kanakura, Y.; Morii, E.; Aozasa, K. Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group. Case. Rep. Oncol., 2009, 2(3), 194-202.
4. Gopal, A.K.; Press, O.W.; Wilbur, S.M.; Maloney, D.G.; Pagel, J.M. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood, 2008, 112(3), 830-835.
5. Moldenhauer, G. CD37. J. Biol. Regul. Homeost. Agents, 2000, 14(4), 281-283.
6. Press, O.W.; Farr, A.G.; Borroz, K.I.; Anderson, S.K.; Martin, P.J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 1989, 49(17), 4906-4912.
7. Press, O.W.; Howell-Clark, J.; Anderson, S.; Bernstein, I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood, 1994, 83(5), 1390-1397.
8. 131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl. Med. Biol., 1997, 24(7), 657-663.
9. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res., 1992, 52(23), 6476-6481.
10. Eary, J.F.; Press, O.W.; Badger, C.C.; Durack, L.D.; Richter, K.Y.; Addison, S.J.; Krohn, K.A.; Fisher, D.R.; Porter, B.A.; Williams, D.L. Imaging and treatment of B-cell lymphoma. J. Nucl. Med., 1990, 31(8), 1257-1268.
11. 131I-labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol., 1992, 10(11), 1696-1711.
12. Press, O.W.; Eary, J.F.; Badger, C.C.; Martin, P.J.; Appelbaum, F.R.; Levy, R.; Miller, R.; Brown, S.; Nelp, W.B.; Krohn, K.A. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol., 1989, 7(8), 1027-1038.
13. Press, O.W.; Eary, J.F.; Appelbaum, F.R.; Martin, P.J.; Badger, C.C.; Nelp, W.B.; Glenn, S.; Butchko, G.; Fisher, D.; Porter, B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 1993, 329(17), 1219-1224.
14. Sharkey, R.M.; Behr, T.M.; Mattes, M.J.; Stein, R.; Griffiths, G.L.; Shih, L.B.; Hansen, H.J.; Blumenthal, R.D.; Dunn, R.M.; Juweid, M.E.; Goldenberg, D.M. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother., 1997, 44(3), 179-188.
15. 111In-DTPA-trastuzumab. Br. J. Pharmacol., 2004, 143(1), 99-106.
16. 90Y-DOTATOC. Cancer Biother. Radiopharm., 2009, 24(6), 659-665.
17. 177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(10), 1788-1797.
18. 177Lutetium-DOTA-Rituximab (177Lu-D-R): A phase I/II-study in 30 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas. 50th ASH annual meeting and exposition, 2010,).
19. 177Lu-DOTA(0),Tyr(3)]octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(7), 1138-1146.
20. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur. J Nucl Med Mol Imaging, 2011, 38(2), 302-311.
21. 177Lu. Appl. Radiat. Isot., 2008, 66(2), 147-151.
22. 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother. Radiopharm., 2003, 18(4), 593-599.
23. Smeland, E.; Funderud, S.; Ruud, E.; Kiil, B.H.; Godal, T. Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor. Scand. J. Immunol., 1985, 21(3), 205-214.
24. Bernstein, I.D.; Eary, J.F.; Badger, C.C.; Press, O.W.; Appelbaum, F.R.; Martin, P.J.; Krohn, K.A.; Nelp, W.B.; Porter, B.; Fisher, D. High dose radiolabeled antibody therapy of lymphoma. Cancer Res., 1990, 50(3 Suppl), 1017s-1021s.
25. Lindmo, T. and Bunn, P.A., Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol., 1986, 121, 678-691.
26. 177Lu. 2012.
27. Yuan, J. Estimation of variance for AUC in animal studies. J. Pharm. Sci., 1993, 82(7), 761-763.
28. 177Lu radionuclides. Cancer Biother. Radiopharm., 2005, 20(4), 436-449.
29. Sparks, R.B. and Aydogan, B. Comparison of the Effectiveness of Some Common Animal Data Scaling Techniques in Estimating Human Radiation Dose. Sixth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, Oak Ridge Associated Universities, 1999, 705-716.
30. Snyder, W.S.; Ford, M.R.; Warner, G.G.; Watson, S.B. MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs (PART 1). 1975,).
31. Radiation Dose Assessment Resource (RADAR) - Available Phantoms. http://www.doseinfo-radar.com/RADARphan.html. 2012.
32. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann. ICRP, 2002, 32(3-4), 52-65.
33. ICRP Publication 70, Basic Anatomical and Physiological Data for Use in Radiological Protection: The skeleton. Ann. ICRP, 1995, 25(2).
34. ICRP Publication 23, Task Group Report on Reference Man. 1975.
35. Vallabhajosula, S.; Goldsmith, S.J.; Hamacher, K.A.; Kostakoglu, L.; Konishi, S.; Milowski, M.I.; Nanus, D.M.; Bander, N.H. Prediction of myelotoxicity based on bone marrow radiation absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med, 2005, 46(5), 850-858.
36. 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J. Nucl. Med., 2012, 53(1), 82-89.
37. Winter, J.N.; Inwards, D.J.; Spies, S.; Wiseman, G.; Patton, D.; Erwin, W.; Rademaker, A.W.; Weitner, B.B.; Williams, S.F.; Tallman, M.S.; Micallef, I.; Mehta, J.; Singhal, S.; Evens, A.M.; Zimmer, M.; Molina, A.; White, C.A.; Gordon, L.I. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 2009, 27(10), 1653-1659.
38. 177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur. J Nucl Med Mol Imaging, 2003, 30(2), 312-315.
39. Muller, W.A.; Linzner, U.; Schaffer, E.H. Organ distribution studies of lutetium-177 in mouse. Int. J. Nucl. Med. Biol., 1978, 5(1), 29-31.
40. U.S. Food and Drug Administration (FDA) - Zevalin Package Insert. 2012.